20080604
 FDA Probes Drugs' Risk for Youths   By Wang, Shirley S, The Wall Street Journal,  Jun 5, 2008  The four drugs under scrutiny are biologic treatments known as tumor necrosis factor inhibitors, or TNF blockers, and include Johnson & Johnson's Remicade, Abbott Laboratories' Humira, Amgen Inc. and Wyeth's Enbrel, and UCB SA's Cimzia.   
